Here's why a Menlo Park drug company is turning from a rare disease to focus on cancer
Starting with a late-stage clinical trial in ovarian cancer, the 24-year-old company is looking to prove that controlling a hormone found in every organ can have an impact beyond its initial rare disease approval a decade ago.
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Ron Leuty Source Type: news
More News: Cancer | Cancer & Oncology | Clinical Trials | Health Management | Hormones | Men | Ovarian Cancer | Ovaries | Pharmaceuticals | Rare Diseases